Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Bassan R, et al. Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13. Blood. 2009. PMID: 19141862 Free article.
Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia.
Bassan R, Lerede T, Di Bona E, Rambaldi A, Rossi G, Pogliani E, Oriani A, D'Emilio A, Izzi T, Lambertenghi-Deliliers G, Corneo G, Barbui T. Bassan R, et al. Br J Haematol. 1999 Mar;104(4):755-62. doi: 10.1046/j.1365-2141.1999.01258.x. Br J Haematol. 1999. PMID: 10192437 Free article. Clinical Trial.
Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia.
Bassan R, Rohatiner AZ, Rambaldi A, Lerede T, Di Bona E, Carter M, Rossi G, Pogliani E, Lambertenghi-Deliliers G, Fabris P, Porcellini A, Lister TA, Barbui T. Bassan R, et al. Adv Exp Med Biol. 1999;457:489-99. doi: 10.1007/978-1-4615-4811-9_53. Adv Exp Med Biol. 1999. PMID: 10500826 Clinical Trial.
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R, Pogliani E, Lerede T, Fabris P, Rossi G, Morandi S, Casula P, Lambertenghi-Deliliers G, Vespignani M, Izzi T, Coser P, Corneo G, Barbui T. Bassan R, et al. Haematologica. 1999 Dec;84(12):1088-93. Haematologica. 1999. PMID: 10586210 Clinical Trial.
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.
Bassan R, Pogliani E, Casula P, Rossi G, Fabris P, Morandi S, Lambertenghi-Deliliers G, Vespignani M, Lerede T, Rambaldi A, Borleri G, Spedini P, Cortelezzi A, Izzi T, Coser P, Broccia G, Corneo G, Barbui T. Bassan R, et al. Hematol J. 2001;2(2):117-26. doi: 10.1038/sj/thj/6200091. Hematol J. 2001. PMID: 11424004 Clinical Trial.
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Micò C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A. Spinelli O, et al. Haematologica. 2007 May;92(5):612-8. doi: 10.3324/haematol.10965. Haematologica. 2007. PMID: 17488684 Free article.
174 results